The biological logic behind the combination is what sets it apart from many single-cell approaches. Solid tumors are not uniform targets; they are heterogeneous collections of malignant cells that deploy overlapping but distinct strategies to evade immune attack. Natural killer cells belong to the innate immune system and can recognize and destroy stressed or abnormal cells without needing to identify a specific tumor antigen, making them valuable against cancer cells that have downregulated the surface molecules T cells typically rely on. T lymphocytes, by contrast, mediate adaptive immunity: when primed against tumor antigens, they can mount targeted, antigen-specific killing and generate immunological memory. By infusing both cell types together, the investigators aimed to attack the tumor through complementary mechanisms, reducing the likelihood that an immune-escape variant could slip through unscathed.

The trial design reflected its early-phase purpose. This was a single-arm study, meaning there was no placebo or control group, and all nine enrolled patients received the active therapy. Each participant had a recurrent or progressive solid tumor and had already undergone between one and three prior lines of systemic treatment, placing them squarely in the population where standard options have been exhausted. SDH-Combi was manufactured from each patient’s own cells—an autologous approach that avoids the rejection risks associated with donor material—and was administered as an infusion once every two weeks, for up to eight infusions in total. The primary endpoint was safety and tolerability, while secondary endpoints included objective response rate, disease control rate, progression-free survival, and overall survival, with tumor measurements assessed according to the widely used RECIST v1.1 criteria.

On the safety front, the results were strikingly clean for a cell therapy. Among the nine treated patients, no grade 3 or higher treatment-related adverse event occurred, a finding the investigators report with a 95 percent confidence interval of 0.0 to 33.6 percent. No patient discontinued treatment because of toxicity, no cases of cytokine release syndrome were observed, and there were no anaphylactic reactions or treatment-related serious adverse events. Cytokine release syndrome—a potentially dangerous inflammatory cascade that has complicated other cellular immunotherapies, most famously CAR T cell treatments—was a particular concern the trial was designed to monitor, and its complete absence is a notable point in the therapy’s favor.

Tolerability metrics reinforced the safety picture. Six of the nine patients, or 66.7 percent, completed all eight planned infusions, and 64 of the 72 planned infusions across the study—88.9 percent—were actually administered, indicating that the treatment schedule was practical for most participants. The single serious adverse event in the trial was a grade 4 anemia in one patient, whose hemoglobin fell to a nadir of 4.5 grams per deciliter, but the investigators judged this event unlikely to be related to the study therapy. All other adverse events were grades 1 or 2, the mildest categories on the standard CTCAE v5.0 grading scale used to classify treatment-emergent events.

The preliminary efficacy signals, while modest, were not negligible. In the full analysis set of nine patients, the disease control rate—encompassing complete responses, partial responses, and stable disease—reached 66.7 percent, suggesting that for a majority of these heavily pretreated patients, the therapy was associated with at least a halt in tumor progression. The objective response rate, which counts only measurable tumor shrinkage, was 11.1 percent, corresponding to a single patient among the nine. Median overall survival had not been reached at the time of the safety assessment, though five of the nine patients had died by the follow-up date of 14 January 2026. The authors are appropriately measured about these numbers, noting that formal statistical inference is limited by the small, single-arm sample size and the absence of a comparator group.

One of the more intriguing aspects of the study is its attention to quality of life, an exploratory endpoint measured with the validated EORTC QLQ-C30 questionnaire. Patients reported improvements that crossed the threshold for a minimal clinically important difference—defined as a change of at least 10 points—in five of the six functional domains assessed: global health status and quality of life, physical functioning, role functioning, emotional functioning, and social functioning. All nine symptom domains also showed changes meeting or approaching that threshold, with constipation showing a marginal improvement of 11.1 points, while cognitive functioning did not reach the clinically important threshold. For a population of patients with advanced, recurrent cancer, subjective improvements in daily functioning and well-being carry real weight, even in an uncontrolled setting where placebo effects and natural fluctuation cannot be excluded.

The trial was conducted under ethical approval from the Institutional Review Board of the Ministry of Health of Mongolia, with clinical sites including hospitals in Ulaanbaatar, and was funded by Seoul Songdo Hospital in South Korea, where the cell processing facility manufactured the autologous products. The collaboration highlights how cellular immunotherapy research is expanding geographically, and the authors acknowledge the substantial manufacturing effort required to produce patient-specific cell products on a clinical schedule. Autologous therapies of this kind demand that a patient’s own immune cells be collected, processed, expanded, and quality-controlled before being reinfused—a logistical and technical undertaking that shapes which patients can be treated and how quickly.

The authors conclude that SDH-Combi was feasible and well tolerated, with preliminary signals of disease stabilization and quality of life improvement in previously treated patients, findings they say support further clinical evaluation of this biologically rational combination cellular immunotherapy. That framing is the appropriate one for a phase 1 study: the trial was never designed to prove efficacy, only to establish that the approach can be delivered safely and consistently. What it has demonstrated is that combining autologous natural killer cells with tumor-primed T lymphocytes can be done without the severe toxicities that have shadowed other cell therapies, and that the treatment can be administered on a demanding every-two-week schedule with most patients completing the full course.

The road ahead will require larger, controlled trials to determine whether the disease control signals translate into meaningful extensions of survival, and which tumor types benefit most. The field of combination cellular immunotherapy is betting on a simple premise: that cancers are too adaptable to be defeated by any single immune cell type, and that deploying innate and adaptive immunity together closes the escape routes tumors rely on. With no grade 3 or higher treatment-related events, nearly 90 percent of planned infusions delivered, and a majority of patients experiencing disease control, this first-in-human evaluation gives that premise its earliest real-world test—and a reason for the field to keep watching.

Subject of Research: Phase 1 trial of autologous NK cell and T lymphocyte combination immunotherapy for recurrent solid tumors

Article Title: Phase 1 clinical trial evaluating the safety and preliminary efficacy of autologous NK cells combined with T lymphocytes in patients with recurrent solid tumors

Article References: Kim, K.-J., Lee, N., Che, D. N., Lee, H.-J., Lee, H. N., Tungalag, S., Batsukh, K., Nyamdavaa, T., Sohn, S.-K., & Lee, J. K. (2026). Phase 1 clinical trial evaluating the safety and preliminary efficacy of autologous NK cells combined with T lymphocytes in patients with recurrent solid tumors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04532-7

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04532-7

Keywords: NK cells, T lymphocytes, cellular immunotherapy, solid tumors, phase 1 trial, autologous therapy, cancer immunotherapy, RECIST, quality of life, cytokine release syndrome, disease control, immune escape

The clinical logic behind platelet-rich plasma, commonly abbreviated PRP, is deceptively simple. Platelets are the blood’s first responders, streaming to sites of injury and releasing a cocktail of growth factors and signaling proteins that orchestrate clotting, inflammation resolution, and tissue rebuilding. By concentrating platelets from a patient’s blood and re-delivering them to a damaged site, clinicians aim to amplify the body’s own repair mechanisms. Because the material is autologous, derived from the patient, it sidesteps immune rejection and disease transmission concerns that complicate donor-derived products. But aging is known to blunt tissue regeneration, raising an uncomfortable question: if regeneration slows with age, does the PRP made from an 80-year-old’s blood still carry the molecular machinery needed to heal?

That is precisely the question addressed by Anna Buisan-Farré, Montserrat Serra-Mas, Marta Otero-Viñas, and colleagues working across the University of Vic – Central University of Catalonia, the Institute for Research and Innovation in Life and Health Sciences in Central Catalonia, and the Institute for Research in Biomedicine in Barcelona. Their study stands out for its focus. Most proteomic investigations of PRP have examined samples from young or mixed-age donors, leaving a substantial evidence gap for the elderly, whose tissues are the ones most in need of regenerative support and whose blood may differ immunologically, hormonally, and in its clotting behavior.

The technical pipeline behind the study reflects the rigor required to make such claims defensible. Blood samples were collected from 32 elderly donors under institutional review board approval with informed written consent. Platelet-rich plasma was prepared by sequential centrifugation, the standard method of separating blood components by density. To release the platelet payload, the researchers activated the platelets with calcium gluconate and heparin, then centrifuged the samples again to strip out residual platelets, leaving behind the soluble protein cargo that a clinician would actually inject. Control plasma samples were processed in parallel to distinguish proteins genuinely concentrated by platelets from those simply circulating in blood.

Mass spectrometry formed the analytical core of the work. Because the most abundant blood proteins, chiefly albumin and immunoglobulins, can mask the rarer signaling molecules of interest, the team first depleted these high-abundance proteins. The remaining proteome was enzymatically digested into peptides and analyzed by liquid chromatography coupled to tandem mass spectrometry, a technique that separates peptides by chemical properties before fragmenting them in the mass spectrometer to infer their amino acid sequences. Bioinformatic pipelines then mapped the identified proteins onto known biological processes using tools such as Gene Ontology biological process annotations and the Kyoto Encyclopedia of Genes and Genomes pathway database.

The headline result is striking: 324 of the 1,378 detected proteins appeared exclusively in the platelet-rich plasma and not in control plasma. Functional analysis showed that the PRP proteome, whether unique to PRP or shared with plasma, was strongly linked to vesicle transport, immune and coagulation processes, cytoskeleton organization, and wound healing. In other words, the concentration step does not merely add platelet fragments; it enriches a coherent biological program centered on the very processes tissue repair demands. Cytoskeleton organization proteins point to cell migration and structural remodeling, while vesicle transport proteins reflect the exosome-rich cargo platelets deliver to injured tissue.

Perhaps the most clinically consequential finding, however, concerns variability. The researchers observed marked inter-individual differences in which proteins were detected across the 32 donor samples, and critically, the proteins showing this person-to-person variability were themselves linked to tissue regeneration processes. That observation carries a double meaning. On one hand, it suggests that not every elderly patient’s PRP preparation will be equally potent, a fact that could explain the notoriously inconsistent results of PRP clinical trials, where some patients respond robustly and others see little benefit. On the other hand, it opens a genuine opportunity for personalized medicine: rapid proteomic or functional screening of a patient’s PRP could, in principle, predict therapeutic quality before injection, or guide dosage and treatment protocols on an individual basis.

The study’s authors are careful about what their data do and do not establish. This is a characterization study, not a clinical trial; it demonstrates that elderly-derived PRP is rich in regenerative proteins and that its composition varies between people, but it does not yet prove that variations in the proteome translate into differences in healing outcomes for patients. Translating these molecular inventories into standardized, efficacy-graded PRP products will require correlating proteomic signatures with clinical endpoints in controlled studies, and the inter-individual variability the team documented is precisely the kind of biological signal that such trials should stratify for.

Still, the implications for an aging global population are considerable. As life expectancy rises, the burden of chronic wounds, osteoarthritis, tendinopathies, and other degenerative conditions grows with it, and the elderly are often the least well served by existing regenerative options. The new proteomic map provides reassurance that age does not strip PRP of its therapeutic cargo: even in advanced age, the platelet concentrate retains a wealth of proteins playing crucial roles in tissue regeneration. At the same time, it hands the field a molecular framework for moving beyond one-size-fits-all formulations toward personalized autologous therapies, where the composition of a patient’s own PRP becomes a measurable, and potentially optimizable, clinical variable. In a therapy long criticized for its biological opacity, that transparency may prove the most regenerative development of all.

The choice of activation agents in the study deserves particular attention, because it shapes what the mass spectrometer ultimately sees. Calcium gluconate mimics the physiological trigger for platelet activation, since rising intracellular calcium is the canonical signal that causes platelet granules to fuse with the cell surface and discharge their contents. Heparin, an anticoagulant, was used alongside it, and the combination allowed the researchers to drive degranulation in a controlled manner before removing the platelet bodies entirely. What remains after this step is the secretome: the soluble proteins, growth factors, and chemokines that would, in a living wound, be released directly at the site of injury. This design choice means the measured proteome approximates the bioactive payload a patient would actually receive, rather than an inventory of intact platelet contents.

The depletion of high-abundance proteins is equally consequential for interpreting the results. Albumin and immunoglobulins dominate blood plasma to such an extent that, undepleted, they can consume the vast majority of the mass spectrometer’s analytical capacity, drowning out low-copy signaling molecules. By removing them first, the team gained sensitivity into the mid- and low-abundance range where many regulatory proteins reside, including those governing extracellular matrix assembly and cell communication. This technical step helps explain why the study resolved nearly 1,400 distinct proteins, a depth of coverage that few earlier PRP characterizations achieved, and why proteins tied to vesicle transport and cytoskeletal dynamics emerged so prominently.

The finding that 324 proteins were detected only in platelet-rich plasma underscores how much the concentration step transforms the starting material. Platelets are not merely passive carriers; they are secretory cells whose alpha granules and dense granules hold a curated cargo accumulated during platelet production in the bone marrow. When activated, this cargo is released together with vesicles and microparticles that can deliver signaling molecules to target cells. The enrichment of vesicle transport proteins in the PRP samples is consistent with this biology, suggesting that the therapeutic effect of PRP may depend not only on soluble growth factors but also on the extracellular vesicles that platelets shed, which are increasingly recognized as mediators of intercellular communication in tissue repair.

The inter-individual variability documented across the 32 donors also invites reflection on its possible origins. Protein detection differences between donors could reflect genuine biological variation in platelet content, differences in circulating plasma proteins, or variation in how each donor’s blood responded to the preparation protocol. Age-related changes in platelet reactivity, chronic low-grade inflammation, comorbidities, and medication use are all plausible contributors in an elderly cohort, although the study design did not dissect these factors individually. What the data establish is that the variability itself concentrates in proteins associated with tissue regeneration, meaning the differences are not random noise scattered across irrelevant functions but are centered on the biology that matters therapeutically.

Methodologically, the work also contributes to reproducibility in a field often criticized for heterogeneity. The researchers reported quality control metrics including false discovery rate control for peptide and protein identification, and they deposited their data in the PRIDE proteomics repository, allowing other laboratories to reanalyze the raw spectra. Such transparency matters because PRP preparations differ widely across clinics in centrifugation protocols, activation methods, and platelet concentrations, making cross-study comparison difficult. A well-annotated molecular reference for elderly-derived PRP, produced under a documented preparation pipeline, gives the field a benchmark against which future formulations can be compared, and a foundation for the stratified clinical trials that will be needed to convert proteomic characterization into therapeutic guidance.

Subject of Research: Proteomic profiling of platelet-rich plasma from elderly individuals for autologous regenerative therapy

Article Title: Comprehensive proteomic profiling of platelet-rich plasma from elderly individuals: insights for autologous therapeutic applications

Article References: Buisan-Farré, A., Serra-Mas, M., Sarri, E., Salgado-Pacheco, V., Arauz-Garofalo, G., Odena-Caballol, A., Vilaseca, M., Gay, M., Ferrer-Solà, M., Masó-Albareda, C., Casals-Zorita, M., & Otero-Viñas, M. (2026). Comprehensive proteomic profiling of platelet-rich plasma from elderly individuals: insights for autologous therapeutic applications. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09630-3

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09630-3

Keywords: platelet-rich plasma, PRP, proteomics, mass spectrometry, elderly, tissue regeneration, regenerative medicine, autologous therapy, wound healing, coagulation, inter-individual variability, Clinical Proteomics